Loading…

0014 TRACE AMINE-ASSOCIATED RECEPTOR 1 REGULATES WAKEFULNESS, BEHAVIORAL ACTIVATION AND EEG SPECTRAL COMPOSITION

Abstract Introduction: Trace amines (TAs) are endogenous amino acid metabolites that are structurally similar to the biogenic amines. TAs are endogenous ligands for trace amine-associated receptor 1 (TAAR1), a GPCR that modulates dopaminergic, serotonergic, and glutamatergic activity. Selective TAAR...

Full description

Saved in:
Bibliographic Details
Published in:Sleep (New York, N.Y.) N.Y.), 2017-04, Vol.40 (suppl_1), p.A5-A5
Main Authors: Schwartz, MD, Black, SW, Morairty, SR, Hoener, MC, Kilduff, TS
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page A5
container_issue suppl_1
container_start_page A5
container_title Sleep (New York, N.Y.)
container_volume 40
creator Schwartz, MD
Black, SW
Morairty, SR
Hoener, MC
Kilduff, TS
description Abstract Introduction: Trace amines (TAs) are endogenous amino acid metabolites that are structurally similar to the biogenic amines. TAs are endogenous ligands for trace amine-associated receptor 1 (TAAR1), a GPCR that modulates dopaminergic, serotonergic, and glutamatergic activity. Selective TAAR1 agonists have been shown to have pro-cognitive, antipsychotic-like, anti-addiction, stress-reducing, weight-reducing, glucose-lowering and wake-promoting activities. We used Taar1 knockout (KO) and over-expressing (OE) mice and TAAR1 agonists to elucidate the role of TAAR1 in sleep/wake. Methods: EEG, EMG, body temperature (Tb) and locomotor activity (LMA) were recorded in Taar1 KO, OE and WT mice. Following a 24h recording to characterize baseline sleep/wake, mice were sleep-deprived (SD) for 6h. In separate experiments, mice were given three doses of the TAAR1 partial agonist RO5263397, caffeine, modafinil or vehicle p.o. Results: Baseline wakefulness was modestly increased in OE compared to WT mice. Baseline theta (4.5-9Hz) and low gamma (30-60Hz) activity was elevated in KO compared to OE mice in NREM and REM sleep. Following SD, both KO and OE mice exhibited a homeostatic sleep rebound. In WT mice, RO5263397 increased waking and reduced NREM and REM sleep, decreased gamma power during wake and NREM, and decreased Tb without affecting LMA; these effects were absent in KO mice and potentiated in OE mice. By contrast, caffeine increased wake time, NREM gamma power, and LMA in all strains compared to vehicle; this effect was attenuated in KO and potentiated in OE mice. Subsequent studies confirmed that motor activation and gamma band activity increases induced by caffeine or modafinil are attenuated in KO mice compared to WT. Conclusion: TAAR1 overexpression increases wakefulness whereas TAAR1 partial agonism strongly increases wakefulness and reduces NREM and REM sleep. These results indicate a modulatory role for TAAR1 in sleep/wake and cortical activity and suggest TAAR1 as a novel target for wake-promoting therapeutics. Support (If Any): NIH R01 NS082876.
doi_str_mv 10.1093/sleepj/zsx050.013
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2503443417</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/sleepj/zsx050.013</oup_id><sourcerecordid>2503443417</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1503-910e086eac281264f76f390ec20e78bc1a2e5424e511725be256e8f006f4f9123</originalsourceid><addsrcrecordid>eNqNUMtOwzAQtBBIlMIHcLPEtWm9jp3H0Ri3jUiTKknLMUojR6IqJMRUAr4eR-EDOO3szuzOahC6BzIHEroLc9K6Oy5-zBfhZE7AvUAT4Jw4oaUv0YSAB04AhF-jG2OOxPYsdCeos4jhIhNSYbGJEuWIPE9lJAr1hDMl1bZIMwwWrnaxHeb4RTyr5S5OVJ7P8KNai32UZiLGQhbRXhRRmmCRPGGlVjjfKlkMnEw32zSPBvIWXTXVyei7vzpFu6Uq5NqJ01UkRezUwIk7vK1J4OmqpgFQjzW-17gh0TUl2g8ONVRUc0aZ5gA-5QdNuaeDhhCvYU0I1J2ih_Fu17cfZ20-y2N77t-tZUmtAWMuA9-qYFTVfWtMr5uy61_fqv67BFIOwZZjsOUYbGmDtTuzcac9d_-Q_wJHUXII</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2503443417</pqid></control><display><type>article</type><title>0014 TRACE AMINE-ASSOCIATED RECEPTOR 1 REGULATES WAKEFULNESS, BEHAVIORAL ACTIVATION AND EEG SPECTRAL COMPOSITION</title><source>Oxford Journals Online</source><source>Alma/SFX Local Collection</source><creator>Schwartz, MD ; Black, SW ; Morairty, SR ; Hoener, MC ; Kilduff, TS</creator><creatorcontrib>Schwartz, MD ; Black, SW ; Morairty, SR ; Hoener, MC ; Kilduff, TS</creatorcontrib><description>Abstract Introduction: Trace amines (TAs) are endogenous amino acid metabolites that are structurally similar to the biogenic amines. TAs are endogenous ligands for trace amine-associated receptor 1 (TAAR1), a GPCR that modulates dopaminergic, serotonergic, and glutamatergic activity. Selective TAAR1 agonists have been shown to have pro-cognitive, antipsychotic-like, anti-addiction, stress-reducing, weight-reducing, glucose-lowering and wake-promoting activities. We used Taar1 knockout (KO) and over-expressing (OE) mice and TAAR1 agonists to elucidate the role of TAAR1 in sleep/wake. Methods: EEG, EMG, body temperature (Tb) and locomotor activity (LMA) were recorded in Taar1 KO, OE and WT mice. Following a 24h recording to characterize baseline sleep/wake, mice were sleep-deprived (SD) for 6h. In separate experiments, mice were given three doses of the TAAR1 partial agonist RO5263397, caffeine, modafinil or vehicle p.o. Results: Baseline wakefulness was modestly increased in OE compared to WT mice. Baseline theta (4.5-9Hz) and low gamma (30-60Hz) activity was elevated in KO compared to OE mice in NREM and REM sleep. Following SD, both KO and OE mice exhibited a homeostatic sleep rebound. In WT mice, RO5263397 increased waking and reduced NREM and REM sleep, decreased gamma power during wake and NREM, and decreased Tb without affecting LMA; these effects were absent in KO mice and potentiated in OE mice. By contrast, caffeine increased wake time, NREM gamma power, and LMA in all strains compared to vehicle; this effect was attenuated in KO and potentiated in OE mice. Subsequent studies confirmed that motor activation and gamma band activity increases induced by caffeine or modafinil are attenuated in KO mice compared to WT. Conclusion: TAAR1 overexpression increases wakefulness whereas TAAR1 partial agonism strongly increases wakefulness and reduces NREM and REM sleep. These results indicate a modulatory role for TAAR1 in sleep/wake and cortical activity and suggest TAAR1 as a novel target for wake-promoting therapeutics. Support (If Any): NIH R01 NS082876.</description><identifier>ISSN: 0161-8105</identifier><identifier>EISSN: 1550-9109</identifier><identifier>DOI: 10.1093/sleepj/zsx050.013</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Caffeine ; Electroencephalography ; REM sleep ; Rodents ; Sleep</subject><ispartof>Sleep (New York, N.Y.), 2017-04, Vol.40 (suppl_1), p.A5-A5</ispartof><rights>Sleep Research Society 2017. Published by Oxford University Press [on behalf of the Sleep Research Society]. All rights reserved. For permissions, please email: journals.permissions@oup.com 2017</rights><rights>Sleep Research Society 2017. Published by Oxford University Press [on behalf of the Sleep Research Society]. All rights reserved. For permissions, please email: journals.permissions@oup.com</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Schwartz, MD</creatorcontrib><creatorcontrib>Black, SW</creatorcontrib><creatorcontrib>Morairty, SR</creatorcontrib><creatorcontrib>Hoener, MC</creatorcontrib><creatorcontrib>Kilduff, TS</creatorcontrib><title>0014 TRACE AMINE-ASSOCIATED RECEPTOR 1 REGULATES WAKEFULNESS, BEHAVIORAL ACTIVATION AND EEG SPECTRAL COMPOSITION</title><title>Sleep (New York, N.Y.)</title><description>Abstract Introduction: Trace amines (TAs) are endogenous amino acid metabolites that are structurally similar to the biogenic amines. TAs are endogenous ligands for trace amine-associated receptor 1 (TAAR1), a GPCR that modulates dopaminergic, serotonergic, and glutamatergic activity. Selective TAAR1 agonists have been shown to have pro-cognitive, antipsychotic-like, anti-addiction, stress-reducing, weight-reducing, glucose-lowering and wake-promoting activities. We used Taar1 knockout (KO) and over-expressing (OE) mice and TAAR1 agonists to elucidate the role of TAAR1 in sleep/wake. Methods: EEG, EMG, body temperature (Tb) and locomotor activity (LMA) were recorded in Taar1 KO, OE and WT mice. Following a 24h recording to characterize baseline sleep/wake, mice were sleep-deprived (SD) for 6h. In separate experiments, mice were given three doses of the TAAR1 partial agonist RO5263397, caffeine, modafinil or vehicle p.o. Results: Baseline wakefulness was modestly increased in OE compared to WT mice. Baseline theta (4.5-9Hz) and low gamma (30-60Hz) activity was elevated in KO compared to OE mice in NREM and REM sleep. Following SD, both KO and OE mice exhibited a homeostatic sleep rebound. In WT mice, RO5263397 increased waking and reduced NREM and REM sleep, decreased gamma power during wake and NREM, and decreased Tb without affecting LMA; these effects were absent in KO mice and potentiated in OE mice. By contrast, caffeine increased wake time, NREM gamma power, and LMA in all strains compared to vehicle; this effect was attenuated in KO and potentiated in OE mice. Subsequent studies confirmed that motor activation and gamma band activity increases induced by caffeine or modafinil are attenuated in KO mice compared to WT. Conclusion: TAAR1 overexpression increases wakefulness whereas TAAR1 partial agonism strongly increases wakefulness and reduces NREM and REM sleep. These results indicate a modulatory role for TAAR1 in sleep/wake and cortical activity and suggest TAAR1 as a novel target for wake-promoting therapeutics. Support (If Any): NIH R01 NS082876.</description><subject>Caffeine</subject><subject>Electroencephalography</subject><subject>REM sleep</subject><subject>Rodents</subject><subject>Sleep</subject><issn>0161-8105</issn><issn>1550-9109</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqNUMtOwzAQtBBIlMIHcLPEtWm9jp3H0Ri3jUiTKknLMUojR6IqJMRUAr4eR-EDOO3szuzOahC6BzIHEroLc9K6Oy5-zBfhZE7AvUAT4Jw4oaUv0YSAB04AhF-jG2OOxPYsdCeos4jhIhNSYbGJEuWIPE9lJAr1hDMl1bZIMwwWrnaxHeb4RTyr5S5OVJ7P8KNai32UZiLGQhbRXhRRmmCRPGGlVjjfKlkMnEw32zSPBvIWXTXVyei7vzpFu6Uq5NqJ01UkRezUwIk7vK1J4OmqpgFQjzW-17gh0TUl2g8ONVRUc0aZ5gA-5QdNuaeDhhCvYU0I1J2ih_Fu17cfZ20-y2N77t-tZUmtAWMuA9-qYFTVfWtMr5uy61_fqv67BFIOwZZjsOUYbGmDtTuzcac9d_-Q_wJHUXII</recordid><startdate>20170428</startdate><enddate>20170428</enddate><creator>Schwartz, MD</creator><creator>Black, SW</creator><creator>Morairty, SR</creator><creator>Hoener, MC</creator><creator>Kilduff, TS</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20170428</creationdate><title>0014 TRACE AMINE-ASSOCIATED RECEPTOR 1 REGULATES WAKEFULNESS, BEHAVIORAL ACTIVATION AND EEG SPECTRAL COMPOSITION</title><author>Schwartz, MD ; Black, SW ; Morairty, SR ; Hoener, MC ; Kilduff, TS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1503-910e086eac281264f76f390ec20e78bc1a2e5424e511725be256e8f006f4f9123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Caffeine</topic><topic>Electroencephalography</topic><topic>REM sleep</topic><topic>Rodents</topic><topic>Sleep</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schwartz, MD</creatorcontrib><creatorcontrib>Black, SW</creatorcontrib><creatorcontrib>Morairty, SR</creatorcontrib><creatorcontrib>Hoener, MC</creatorcontrib><creatorcontrib>Kilduff, TS</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database (ProQuest)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Sleep (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schwartz, MD</au><au>Black, SW</au><au>Morairty, SR</au><au>Hoener, MC</au><au>Kilduff, TS</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>0014 TRACE AMINE-ASSOCIATED RECEPTOR 1 REGULATES WAKEFULNESS, BEHAVIORAL ACTIVATION AND EEG SPECTRAL COMPOSITION</atitle><jtitle>Sleep (New York, N.Y.)</jtitle><date>2017-04-28</date><risdate>2017</risdate><volume>40</volume><issue>suppl_1</issue><spage>A5</spage><epage>A5</epage><pages>A5-A5</pages><issn>0161-8105</issn><eissn>1550-9109</eissn><abstract>Abstract Introduction: Trace amines (TAs) are endogenous amino acid metabolites that are structurally similar to the biogenic amines. TAs are endogenous ligands for trace amine-associated receptor 1 (TAAR1), a GPCR that modulates dopaminergic, serotonergic, and glutamatergic activity. Selective TAAR1 agonists have been shown to have pro-cognitive, antipsychotic-like, anti-addiction, stress-reducing, weight-reducing, glucose-lowering and wake-promoting activities. We used Taar1 knockout (KO) and over-expressing (OE) mice and TAAR1 agonists to elucidate the role of TAAR1 in sleep/wake. Methods: EEG, EMG, body temperature (Tb) and locomotor activity (LMA) were recorded in Taar1 KO, OE and WT mice. Following a 24h recording to characterize baseline sleep/wake, mice were sleep-deprived (SD) for 6h. In separate experiments, mice were given three doses of the TAAR1 partial agonist RO5263397, caffeine, modafinil or vehicle p.o. Results: Baseline wakefulness was modestly increased in OE compared to WT mice. Baseline theta (4.5-9Hz) and low gamma (30-60Hz) activity was elevated in KO compared to OE mice in NREM and REM sleep. Following SD, both KO and OE mice exhibited a homeostatic sleep rebound. In WT mice, RO5263397 increased waking and reduced NREM and REM sleep, decreased gamma power during wake and NREM, and decreased Tb without affecting LMA; these effects were absent in KO mice and potentiated in OE mice. By contrast, caffeine increased wake time, NREM gamma power, and LMA in all strains compared to vehicle; this effect was attenuated in KO and potentiated in OE mice. Subsequent studies confirmed that motor activation and gamma band activity increases induced by caffeine or modafinil are attenuated in KO mice compared to WT. Conclusion: TAAR1 overexpression increases wakefulness whereas TAAR1 partial agonism strongly increases wakefulness and reduces NREM and REM sleep. These results indicate a modulatory role for TAAR1 in sleep/wake and cortical activity and suggest TAAR1 as a novel target for wake-promoting therapeutics. Support (If Any): NIH R01 NS082876.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/sleepj/zsx050.013</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0161-8105
ispartof Sleep (New York, N.Y.), 2017-04, Vol.40 (suppl_1), p.A5-A5
issn 0161-8105
1550-9109
language eng
recordid cdi_proquest_journals_2503443417
source Oxford Journals Online; Alma/SFX Local Collection
subjects Caffeine
Electroencephalography
REM sleep
Rodents
Sleep
title 0014 TRACE AMINE-ASSOCIATED RECEPTOR 1 REGULATES WAKEFULNESS, BEHAVIORAL ACTIVATION AND EEG SPECTRAL COMPOSITION
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T22%3A26%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=0014%20TRACE%20AMINE-ASSOCIATED%20RECEPTOR%201%20REGULATES%20WAKEFULNESS,%20BEHAVIORAL%20ACTIVATION%20AND%20EEG%20SPECTRAL%20COMPOSITION&rft.jtitle=Sleep%20(New%20York,%20N.Y.)&rft.au=Schwartz,%20MD&rft.date=2017-04-28&rft.volume=40&rft.issue=suppl_1&rft.spage=A5&rft.epage=A5&rft.pages=A5-A5&rft.issn=0161-8105&rft.eissn=1550-9109&rft_id=info:doi/10.1093/sleepj/zsx050.013&rft_dat=%3Cproquest_cross%3E2503443417%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1503-910e086eac281264f76f390ec20e78bc1a2e5424e511725be256e8f006f4f9123%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2503443417&rft_id=info:pmid/&rft_oup_id=10.1093/sleepj/zsx050.013&rfr_iscdi=true